The review, co-led by Dr. Dan Theodorescu of the University of Arizona Cancer Center and Dr. Dena B. Dubal of the University of California, San Francisco, synthesizes a growing body of evidence from human studies, mouse models, and advanced genomic technologies. The authors argue that the genes located on the sex chromosomes provide specific instructions that shape cellular function throughout an individual’s lifespan. These genetic signals operate both in isolation and in concert with hormonal pathways, creating a dual-layered system of biological regulation. By integrating these disparate findings, the study provides a unified framework for understanding how sex-specific biology influences major disease categories, including cancer, neurological conditions, and cardiometabolic disorders.

In female biology, the mechanism of X-chromosome inactivation is a central theme of the research. Although one of the two X chromosomes is largely silenced early in development to balance gene dosage with males, this process is not absolute. The review highlights that certain genes on the inactive X chromosome remain active, and others can re-activate with age. This phenomenon results in female cells possessing extra doses of specific genetic material compared to male cells. Furthermore, the origin of the active X chromosome appears to be biologically significant. Studies in mouse models indicate that whether the active X is inherited from the mother or the father can influence physiological outcomes. Mice whose cells predominantly relied on the maternal X chromosome exhibited accelerated brain aging and memory decline, suggesting that the parental origin of sex-linked genes has tangible effects on neurodegeneration and cognitive health.

The stability of sex chromosomes also declines with age, a process that has profound implications for disease susceptibility. The review details how cells can lose an entire sex chromosome over time, a phenomenon known as aneuploidy. In women, the loss of an X chromosome is specifically linked to an increased risk of leukemia, although the broader systemic effects of this loss are still being characterized. In men, the loss of the Y chromosome, which is most commonly measured in circulating blood cells, is associated with a wide array of age-related pathologies. These include various cancers, cardiovascular disease, severe infections, and Alzheimer’s disease. The loss of these chromosomes is increasingly being explored not just as a consequence of aging, but as a potential biomarker and even a causal contributor to the development of chronic diseases.

The implications for oncology are particularly striking, as the research provides a mechanistic explanation for sex-based differences in cancer outcomes. Dr. Theodorescu’s laboratory has previously demonstrated that tumors which lose the Y chromosome gain the ability to evade the immune system. This immune evasion provides a biological rationale for why the loss of the Y chromosome has been statistically linked to increased mortality from carcinomas in men. However, the review also notes a paradoxical therapeutic advantage: tumors that have lost the Y chromosome may respond more favorably to immunotherapy. Understanding this complex interplay between chromosomal loss and immune surveillance could allow clinicians to tailor treatment strategies based on the specific genetic profile of a patient’s tumor, moving toward a more personalized approach to cancer care.

Beyond cancer, the review underscores the role of sex chromosomes in cardiovascular and metabolic health. The genetic instructions on the X and Y chromosomes influence how the heart and metabolic systems respond to stress and aging. By identifying these non-hormonal pathways, the study suggests that current diagnostic tools and treatment protocols may be overlooking critical variables. For instance, the differential expression of X-linked genes in heart tissue could explain why men and women present with and respond to heart disease in distinct ways. Integrating sex-chromosome analysis into cardiometabolic research could lead to the development of targeted therapies that address the root genetic causes of these conditions, rather than merely managing their symptoms.

The origins of this comprehensive review can be traced to discussions at the 2025 National Institute on Aging Workshop, which focused on sex differences impacting human health across the lifespan. The collaboration between researchers from the University of Arizona, UC San Francisco, Northwestern University, and other institutions reflects a broader scientific movement toward recognizing sex as a biological variable in all areas of medical research. The authors emphasize that this work is intended to stimulate further investigation and raise awareness of the significant potential of studying sex chromosomes in the context of disease. By highlighting the far-reaching diagnostic and therapeutic implications of this research, the review aims to bridge the gap between basic genetic science and clinical application.

The study also highlights the importance of designing clinical trials that are sex-aware. Historically, many clinical trials have treated men and women as a homogeneous group, often under-representing one sex or failing to analyze outcomes by sex. The review argues that when clinical trials are designed to account for these cellular differences, researchers can translate scientific findings into personalized medical care more effectively. This approach ensures that treatments and diagnostics are tailored to match every patient’s unique genetic profile, rather than relying on population averages that may mask critical sex-specific variations. Such a shift would enhance the precision of medicine and improve outcomes for both male and female patients.

Previous research from Dr. Theodorescu’s group has further illuminated the role of Y-chromosome loss in immune cells. The team found that the loss of the Y chromosome in T cells and cancer cells in men provides tumors with the ability to evade immune detection. This finding offers a concrete explanation for the observed link between Y-chromosome loss and increased mortality from carcinomas. Additionally, recent studies have shown that the loss of the Y chromosome in normal-appearing tissues can serve as an early warning sign of genetic instability. This loss may mark a hidden zone of risk where cancer is likely to develop, providing a potential window for early intervention and prevention. These findings collectively paint a picture of the Y chromosome as a critical regulator of genomic stability and immune function.

Ultimately, this review represents a significant step forward in understanding the biological basis of sex differences in health and disease. By demonstrating that the X and Y chromosomes are active participants in health and disease throughout a person’s life, the study challenges the traditional view of these chromosomes as mere determinants of sex. The research opens new avenues for exploring how sex-specific genetic mechanisms can be leveraged to improve diagnosis, treatment, and prevention of major diseases. As the field of sex-aware medicine continues to grow, the insights provided by this review will likely play a crucial role in shaping future research agendas and clinical practices, ensuring that the unique biology of both men and women is fully accounted for in the pursuit of better health outcomes.

Subject of Research: The role of X and Y chromosomes in determining disease risk, aging, and physiological health independent of hormonal influences.

Article Title: Study: Sex chromosomes drive how bodies deal with cancer, heart health and longevity

Article References: Study: Sex chromosomes drive how bodies deal with cancer, heart health and longevity. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: sex chromosomes, cancer biology, aging, genetics, cardiovascular health, immunology, precision medicine, X-chromosome inactivation, Y-chromosome loss, biomarkers, clinical trials, neurodegeneration

Every cell in a man’s body normally carries one X chromosome and one Y chromosome. The phenomenon known as loss of Y, sometimes called mosaic loss of the Y chromosome, occurs when individual cells drop their Y chromosome as they divide over the course of a lifetime. Previous studies established that this change is widespread in men as they age and that when it occurs in immune cells circulating in the blood it is associated with elevated risk of a range of diseases. What remained unknown was whether the same process was happening in solid organs, and if so, whether it had any relationship to the development of cancer in those organs.

The new study set out to answer that question systematically. Rather than looking at a single tissue type, the research team profiled Y chromosome loss across normal, precancerous and malignant tissue drawn from 11 major human organs. The scale of the effort was considerable. The investigators analyzed 1,000 tissue samples from 405 men and used an automated fluorescent imaging system to inspect more than 4.3 million individual cell nuclei. By measuring the ratio of Y to X chromosomes in each nucleus, they could quantify precisely how much of the chromosome had been lost in every region of tissue they examined.

The most striking findings came from a portion of the study focused on bladder tissue removed during cancer surgery. The researchers built detailed maps of these surgical specimens, charting exactly where Y chromosome loss appeared across each sample. The maps revealed a clear spatial pattern. Y chromosome loss increased progressively as the tissue moved from visibly normal bladder lining, through early abnormal cells, and finally into full-blown cancer. The change behaved like a slope that grows steadily steeper, rising in intensity with every step toward malignancy.

That gradient extended beyond the bladder. When the team compared normal-appearing tissue adjacent to tumors across different organs, they found the highest levels of Y chromosome loss in tissue surrounding cancers of the colon, rectum, esophagus, pancreas and lung. In other words, the chromosome was disappearing most aggressively in the healthy-looking neighborhoods immediately surrounding tumors, even though those regions contained no cancer cells themselves. The observation points to what cancer biologists call a pre-neoplastic field effect, a hidden zone of genetic vulnerability within apparently normal tissue that provides fertile ground for a tumor to develop.

We were able to show that the loss of the Y chromosome is found in normal appearing tissues adjacent to a tumor, said Theodorescu, the paper’s senior author and holder of the Nancy C. and Craig M. Berge endowed chair for the director of the Cancer Center. That finding is what makes this discovery so exciting. It suggests we may be looking at one of the earliest signposts of cancer forming. The statement captures why the result has generated attention well beyond the field of cancer genetics: if Y chromosome loss marks tissue before tumors appear, it could serve as an early warning signal visible in ordinary biopsy material.

Theodorescu, who is also a professor at the University of Arizona College of Medicine in Tucson, described the pattern with a landscape metaphor. We are now thinking of this as a gradient, similar to a hillside that slowly gets steeper, he said. The closer the tissue is to a cancer, the more Y chromosome loss we see. That gradient could one day help doctors suspect trouble in biopsies that miss a smaller cancer. The clinical implication is significant. Pathologists currently assess biopsy samples for visible abnormalities, but a cancer can be missed if the needle or instrument samples only normal-appearing tissue. A measurable molecular signal, present even in that normal tissue, could alert clinicians that something malignant lies nearby.

The new findings also build on Theodorescu’s earlier work on the biology of Y chromosome loss inside tumors themselves. His previous research showed that when cancer cells lose their Y chromosome, they gain the ability to evade the immune system, an effect that helps explain why loss of the chromosome has been linked in earlier studies to increased mortality from carcinomas. Taken together, the two lines of research sketch a coherent arc. Loss of Y may first render normal tissue more permissive to malignant transformation, and then, once cancer has taken hold, help the tumor hide from the immune defenses that would otherwise destroy it. The chromosome, in this view, is not a passive passenger but a participant at multiple stages of the disease.

How exactly the loss of a single chromosome produces these effects remains an open question. The Y chromosome carries genes involved in immune signaling and cellular regulation, and its disappearance from cells in blood has been linked in prior research to inflammatory and age-related conditions. In solid tissue, the progressive gradient observed in this study suggests that the loss is not random noise but something tied to the local biology of a forming tumor, whether as a cause, a consequence, or both. Disentangling those possibilities is the next challenge for the field, and the pan-organ mapping approach used here provides a framework for pursuing it at scale.

The study was a collaborative effort involving first authors Arkadiusz Gertych and Dr. Huihui Ye, along with collaborators from Cedars-Sinai Medical Center, Fred Hutchinson Cancer Center, the University of Washington and the University of California San Francisco. The work was funded in part by the National Cancer Institute, a division of the National Institutes of Health, under award No. R35CA294022 to Theodorescu. The research was published in JCI Insight on September 8, 2026, under the title Human Y chromosome pan-organ mapping reveals progressive mosaic loss from normal to cancer, and the authors declared no conflicts of interest. For millions of aging men, the finding reframes a familiar genetic change as a potential early alarm, one that could eventually be read from a routine biopsy long before a tumor announces itself.

Subject of Research: Mosaic loss of the Y chromosome in normal tissue as an early indicator of cancer development in men.

Article Title: Loss of Y chromosome in men could be early warning sign of cancer

Article References: Loss of Y chromosome in men could be early warning sign of cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Y chromosome loss, cancer, mosaic loss of Y, bladder cancer, pre-neoplastic field effect, JCI Insight, University of Arizona Cancer Center, fluorescent imaging, aging genetics, tumor microenvironment, immune evasion, pan-organ mapping